The Galil Medical IceRod CX Cryoablation Needle is intended for cryoablative destruction of tissue during surgical procedures. The IceRod CX Cryoablation Needle is indicated for use as a cryosurgical tool in the fields of general surgery, dermatology, neurology (including cryoanalgesia), thoracic surgery (with the exception of cardiac tissue), ENT, gynecology, oncology, proctology, and urology. The systems are designed to destroy tissue by the application of extreme cold temperatures including prostate and kidney tissue, liver metastases, tumors, skin lesions, and warts.

The Galil Medical IceRod CX Cryoablation Needle has the following specific indications:

Urology (ablation of prostate tissue in cases of prostate cancer and Benign Prostate Hyperplasia "BPH")
. Oncology (ablation of cancerous or malignant tissue and benign tumors, and palliative intervention)
. Dermatology (ablation or freezing of skin cancers and other cutaneous disorders. Destruction of warts or lesions, angiomas, sebaceous hyperplasia, basal cell tumors of the eyelid or canthus area, ulcerated basal cell tumors, dermatofibromas small hemanglomas. mucocele cysts, multiple warts, plantar warts, actinic and seborrheic keratoses, cavernous hemanglomas, perianal condylomata, and palliation of tumors of the skin.)
. Gynecology (ablation of malignant neoplasia or benign dysplasia of the female genitalia)
. General surgery (palliation of tumors of the rectum, hemorrhoids, anal fissures, pilonidal cysts, and recurrent cancerous lesions, ablation of breast fibroadenoma)
. ENT (Palliation of tumors of the oral cavity and ablation of leukoplakia of the mouth)
. Thoracic surgery (with the exception of cardiac tissue)
. Proctology (ablation of benign or malignant growths of the anus or rectum, and hemorrhoids)

Device Description

Galil is requesting clearance of a laser marking process improvement technique used to create the "markings" on the needle shaft of the previously cleared IceRod CX Needle (K121251). Galil's IceRod CX Needle (K121251) is a sterile, single use, disposable component used in conjunction with Galil Medical's Visual-ICE Cryoablation System (K113860, K123865) when performing cryoablative destruction of tissue. The needle has a sharp cutting tip, a 1.5mm (17G) shaft, a color-coded handle, gas tubing, and a connector. The handle is in a 90° configuration to aid positioning of the needle within the CT imaging system gantry. The IceRod CX needle contains shaft markings to aid the physician in needle placement. There are no changes to the marking dimensions on the needle. Only the marking technique has been modified.

Since Galil is requesting clearance for a revised shaft marking process improvement technique for the IceRod CX Cryoablation Needle design itself (with the exception of the shaft marking method) has not changed. There are no other design, specification, process, or material changes to the needle; additionally, the model number of the needle is unchanged.

AI/ML Overview

This document is a 510(k) summary for the IceRod CX Cryoablation Needle, focusing on an improved laser marking process for the needle shaft. It primarily establishes substantial equivalence to a previously cleared device (K121251) rather than presenting a detailed clinical study with acceptance criteria in the typical sense for a brand new device or algorithm.

Therefore, many of the requested categories (e.g., sample size for test set, number of experts for ground truth, adjudication method, MRMC study, sample size for training set, ground truth for training set) are not applicable to the type of submission described. This submission is for a process improvement to an existing device, not a new diagnostic or therapeutic algorithm.

Here's a breakdown of the available information:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state quantitative acceptance criteria in the typical format of a new medical device submission (e.g., sensitivity, specificity, accuracy thresholds). Instead, the acceptance criteria are implicit in demonstrating that the new laser marking process does not negatively impact the needle's integrity, safety, or performance characteristics compared to the predicate device.

Acceptance Criteria (Implied)	Reported Device Performance
No impact on needle integrity	Shaft qualification testing conducted to ensure no impact.
No impact on safety	Testing conducted to verify safety characteristics.
No impact on performance characteristics	Testing conducted to verify performance characteristics.
Laser marking does not affect the heat-affected zone	Heat affected zone measurements conducted.
Laser marking quality and adherence to specifications	Shaft marking quality and adherence to specifications evaluated.
Device design remains the same (except marking technique)	Confirmed.
Materials remain the same	Confirmed.
Principle of operation remains the same	Confirmed.
Mechanism of action remains the same	Confirmed.
Indications for Use remain the same	Confirmed.
Device functions remain the same (Freezing/Thawing Technology, Function, Freezing Parameters, Thaw Parameters, Tract Ablation)	Confirmed.

2. Sample size used for the test set and the data provenance

Sample Size: Not explicitly stated as a "test set" in the context of clinical performance. The document describes "shaft qualification testing," "heat affected zone measurements," and "shaft marking quality and adherence to specifications." The specific number of needles tested for these engineering/bench tests is not provided.
Data Provenance: Not applicable in the context of clinical data. It's bench testing data conducted by Galil Medical.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

Not applicable. Ground truth, in the sense of expert consensus on medical findings, is not relevant for this engineering-focused submission. The "ground truth" here is adherence to engineering specifications and performance parameters.

4. Adjudication method for the test set

Not applicable. No expert adjudication process is described.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This submission is for a medical device (cryoablation needle), not an AI/CAD device, and therefore, an MRMC study is not relevant.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

Not applicable. This is not an algorithm or AI device.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

The "ground truth" for this submission is based on engineering specifications, performance metrics, and safety standards derived from the predicate device and established manufacturing/quality control processes. This involves physical measurements, stress tests, and evaluations against pre-defined limits for mechanical integrity, thermal properties, and visual quality of the markings.

8. The sample size for the training set

Not applicable. This is not a machine learning or AI device that requires a training set.

9. How the ground truth for the training set was established

Not applicable.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for Galil Medical. The logo consists of a stylized letter G with a circle and line inside, followed by the text "GALILMEDICAL" in a bold, sans-serif font. Below the company name is the tagline "Leading Through Innovation" in a smaller font.

510(k) SUMMARY

A summary of 510(k) safety and effectiveness information in accordance with the requirements of 21 CFR 807.92.

Submitter:	Galil Medical Ltd.Tavor 1 BuildingShaar YokneamYokneam Industrial Park 20692Israel
Company Contact Person:	Ms. Lynne A DaviesSr. Regulatory Affairs AdvisorGalil Medical Inc.Phone: 651-287-5098Fax: 651-287-5099Email: lynne.davies@galilmedical.com
Alternate Contact Person:	Ms. Amy E McKinneySr Director, Global Regulatory Affairs and QualityGalil Medical Inc.Phone: 651-287-5096Fax: 651-287-5097Email: amy.mckinney@galilmedical.com
Device Name:	IceRod CX Cryoablation Needle
Device ClassificationName:	Cryosurgical unit and accessories (GEH)21 CFR 878.4350
Predicate Devices /Referenced 510(k):	IceRod CX Cryoablation Needle (K121251)
Date of Preparation	March 6. 2014

Device Description:

{1}------------------------------------------------

Image /page/1/Picture/0 description: The image shows the logo for Galil Medical. The logo consists of a stylized letter "G" with a small circle inside, followed by the text "GALILMEDICAL" in bold, sans-serif font. Below the company name is the tagline "Leading Through Innovation" in a smaller, less bold font.

Table 1 provides a summary comparison of the changes related to the shaft marking process for Galil's IceRod CX.

Table 1 Summary of Changes
Description of Device	Comments related to the previously cleared IceRod CX(K121251)
Design and Construction
Needle Tip	Same
Needle Shaft	Same
Needle Shaft Marks	Same
Needle Shaft Marking Material	Laser marking process replaces the Electro Etching process
Needle Shaft Marking Technique	Laser marking process replaces the Electro Etching process
Gas Pathway Tubing	Same
Handle	Same
Needle Connector	Same
Performance and Function
Freezing/Thawing Technology	Same
Function	Same
Freezing Parameters	Same
Thaw Parameters	Same
Track Ablation	Same
Indications for Use	Same

Therefore as outlined in Table 1 the IceRod CX Needle, incorporating the revised shaft marking technique, has the same:

. device design;
. materials;
. principle of operation: and
. mechanism of action.

Intended Use:

There have been no changes to the Indications for Use Statement as a result of the modifications contained in this Special 510(k) from that cleared via Galil's IceRod CX K121251.

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the logo for Galil Medical. The logo consists of a stylized letter G with a small circle inside, followed by the text "GALILMEDICAL" in bold, sans-serif font. Below the company name is the tagline "Leading Through Innovation" in a smaller, sans-serif font.

The Galil Medical IceRod CX Cryoablation Needle has the following specific indications:

Urology (ablation of prostate tissue in cases of prostate cancer and Benign Prostate Hyperplasia "BPH")
. Oncology (ablation of cancerous or malignant tissue and benign tumors, and palliative intervention)
. Dermatology (ablation or freezing of skin cancers and other cutaneous disorders. Destruction of warts or lesions, angiomas, sebaceous hyperplasia, basal cell tumors of the eyelid or canthus area, ulcerated basal cell tumors, dermatofibromas small hemanglomas. mucocele cysts, multiple warts, plantar warts, actinic and seborrheic keratoses, cavernous hemanglomas, perianal condylomata, and palliation of tumors of the skin.)
. Gynecology (ablation of malignant neoplasia or benign dysplasia of the female genitalia)
. General surgery (palliation of tumors of the rectum, hemorrhoids, anal fissures, pilonidal cysts, and recurrent cancerous lesions, ablation of breast fibroadenoma)
. ENT (Palliation of tumors of the oral cavity and ablation of leukoplakia of the mouth)
. Thoracic surgery (with the exception of cardiac tissue)
. Proctology (ablation of benign or malignant growths of the anus or rectum, and hemorrhoids)

Summary of Performance Data and Substantial Equivalence:

The IceRod CX needle design, with the exception of the laser marking process improvement technique for the "markings" on the needle shaft, remains the same and therefore, the design verification testing located in Section 18 Performance Testing - Bench provided in K121251 is applicable. Therefore, since the shaft marking technology is the only change being made to Gali's IceRod CX needle, Galil Medical conducted shaft qualification testing, heat affected zone measurements and shaft marking quality and adherence to specifications. The tests were conducted to ensure the laser marking on the needle shaft does not impact the needle integrity and thereby verify safety and performance characteristics and to establish substantial equivalence.

Conclusion:

Galil Medical believes the information and data provided in this Special 510(k) Notification establishes that the IceRod CX Needle utilizing the laser marking process improvement technique to "mark" the needle shaft does not affect safety or effectiveness, or raise different questions of safety and effectiveness from that cleared in the original IceRod CX 510(k) K121251 and is therefore, substantially equivalent to the legally marketed predicate device.

{3}------------------------------------------------

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

March 31, 2014

Galil Medical Ltd. Ms. Lynne A. Davies Senior Regulatory Affairs Advisor 4364 Round Lake Road Arden Hills, Minnesota 55112

Re: K140584

Trade/Device Name: IceRod CX Cryoablation Needle Regulation Number: 21 CFR 878.4350 Regulation Name: Cryosurgical unit and accessories Regulatory Class: Class II Product Code: GEH Dated: March 6, 2014 Received: March 7, 2014

Dear Ms. Davies:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA 's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

Image /page/3/Picture/11 description: The image is a circular seal for the Department of Health & Human Services USA. The seal features the department's emblem, which is a stylized depiction of an eagle with three lines representing its wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the top half of the circle, while the bottom half reads "DEPARTMENT OF HEALTH & HUMAN SERVICES" in a similar circular arrangement.

{4}------------------------------------------------

Page 2 - Ms. Lynne A. Davies

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Felipe Aquel

Binita S. Ashar, M.D., M.B.A., F.A.C.S. for Acting Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Indications for Use Statement

510(k) Number (if known): K140584

Device Name: IceRod CX Cryoablation Needle

Indications For Use:

The Galil Medical IceRod CX Cryoablation Needle has the following specific indications:

Urology (ablation of prostate tissue in cases of prostate cancer and Benjon Prostate Hyperplasia "BPH")
. Oncology (ablation of cancerous or malignant tissue and benign tumors, and palliative intervention)
. Dermatology (ablation or freezing of skin cancers and other cutaneous disorders. Destruction of warts or lesions, angiomas, sebaceous hyperplasia, basal cell tumors of the eyelid or canthus area, ulcerated basal cell tumors, dermatofibromas small hemanglomas, mucocele cysts, multiple warts, actinic and seborrheic keratoses, cavernous hemanglomas, perianal condylomata, and palliation of tumors of the skin.)
Gynecology (ablation of malignant neoplasia or benign dysplasia of the female genitalia) .
General surgery (palliation of tumors of the rectum, hemorrhoids, anal fissures, pilonidal . cvsts, and recurrent cancerous lesions, ablation of breast fibroadenoma)
ENT (Palliation of turnors of the oral cavity and ablation of leukoplakia of the mouth) .
Thoracic surgery (with the exception of cardiac tissue) .
Proctology (ablation of benign or malignant growths of the anus or rectum, and . hemorrhoids)

AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR AND/OR Over-The-Counter Use Prescription Use X (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Regulation Number and Section

§ 878.4350 Cryosurgical unit and accessories.

(a)
Identification —(1)Cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories. A cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold.(2)
Cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories. A cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures, including urological applications, by applying extreme cold.(3)
Cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories. A cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. The device is intended to treat disease conditions such as tumors, skin cancers, acne scars, or hemangiomas (benign tumors consisting of newly formed blood vessels) and various benign or malignant gynecological conditions affecting vulvar, vaginal, or cervical tissue. The device is not intended for urological applications.(b)
Classification. Class II.